Deep Track reports 1.96M Attovia common share equivalent

Attovia Therapeutics, Inc. reports that Deep Track Biotechnology Master Fund, Ltd., together with affiliated entities Deep Track Capital, LP and David Kroin, has an initial reported position in Series C Redeemable Convertible Preferred Stock.

Rhea-AI Filing Summary

Attovia Therapeutics, Inc. reports that Deep Track Biotechnology Master Fund, Ltd., together with affiliated entities Deep Track Capital, LP and David Kroin, has an initial reported position in Series C Redeemable Convertible Preferred Stock. This preferred stock is convertible into 1,957,138 shares of common stock at a fixed 9.29-for-one conversion ratio and has no expiration date. The preferred shares are held by Deep Track Biotechnology Master Fund, Ltd., with Deep Track Capital, LP as investment manager and David Kroin as managing member of the general partner; the latter two disclaim beneficial ownership except to the extent of their pecuniary interests.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Deep Track Biotechnology Master Fund, Ltd., Deep Track Capital, LP, KROIN DAVID

Role 10% Owner | 10% Owner | 10% Owner

Type	Security	Shares	Price	Value
holding	Series C Redeemable Convertible Preferred Stock F1, F2	--	--	--

Holdings After Transaction: Series C Redeemable Convertible Preferred Stock — 1,957,138 contracts (Direct)

Footnotes (2)

1. F1. Each share of Series C Redeemable Convertible Preferred Stock ("Series C Preferred Stock") is convertible at any time at the option of the holder and will automatically convert into shares of the Issuer's common stock ("Common Stock") upon the closing of the Issuer's initial public offering at the applicable conversion ratio of 9.29-for-one. The Series C Preferred Stock has no expiration date.
2. F2. Represents securities held by Deep Track Biotechnology Master Fund, Ltd. Deep Track Capital, LP is the investment manager of Deep Track Biotechnology Master Fund, Ltd. Mr. David Kroin is the managing member of Deep Track Capital GP, LLC, the general partner of Deep Track Capital, LP, and by virtue of such status may be deemed to be the beneficial owner of the shares owned by Deep Track Biotechnology Master Fund, Ltd. Deep Track Capital, LP and Mr. Kroin disclaim beneficial ownership of such shares except to the extent of their respective pecuniary interests..

Key Figures

Underlying common shares: 1,957,138 shares Conversion ratio: 9.29-for-one Preferred shares position: 1,957,138.0000 (Series C)

3 metrics

Underlying common shares 1,957,138 shares Common stock underlying Series C Redeemable Convertible Preferred Stock position

Conversion ratio 9.29-for-one Conversion ratio of Series C Preferred Stock into common stock

Preferred shares position 1,957,138.0000 (Series C) Total shares of Series C Redeemable Convertible Preferred Stock reported as directly held

Key Terms

Series C Redeemable Convertible Preferred Stock, conversion ratio, beneficial owner, pecuniary interests

4 terms

Series C Redeemable Convertible Preferred Stock financial

"Reports holdings of Series C Redeemable Convertible Preferred Stock convertible into common stock"

conversion ratio financial

"will automatically convert into shares of common stock at the applicable conversion ratio of 9.29-for-one"

The conversion ratio is the number of common shares an investor receives when a convertible security (like a bond or preferred share) or an exchangeable instrument is turned into ordinary stock. It matters because it tells investors how much ownership or dilution will occur — similar to knowing how many slices you get when you trade in a coupon — and directly affects the value you get from the convertible and the company’s future share count.

beneficial owner financial

"may be deemed to be the beneficial owner of the shares owned by Deep Track Biotechnology Master Fund"

A beneficial owner is the person who ultimately owns or controls a financial asset or property, even if their name isn't directly on official documents. Think of it like someone who secretly holds the keys to a safe deposit box—others may appear to have access, but the true owner is the one who benefits from what's inside. Identifying beneficial owners helps ensure transparency and prevent illegal activities like money laundering or fraud.

pecuniary interests financial

"disclaim beneficial ownership of such shares except to the extent of their respective pecuniary interests"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What ownership in Attovia Therapeutics (ATTO) does Deep Track report on this Form 3?

Deep Track reports holdings of Series C Redeemable Convertible Preferred Stock convertible into 1,957,138 common shares of Attovia Therapeutics, Inc. This reflects an initial statement of beneficial ownership, not a new transaction.

How can Deep Track’s preferred shares in Attovia Therapeutics (ATTO) convert into common stock?

Each share of Series C Preferred Stock is convertible into common stock at the holder’s option and will automatically convert upon Attovia’s initial public offering at a 9.29-for-one conversion ratio, with no expiration date on the preferred shares.

Who is the direct holder of the Attovia Therapeutics (ATTO) preferred shares on this Form 3?

The reported securities are held by Deep Track Biotechnology Master Fund, Ltd.. Deep Track Capital, LP acts as its investment manager, and David Kroin is managing member of the general partner of Deep Track Capital, LP.

Do Deep Track Capital, LP and David Kroin fully own the reported Attovia (ATTO) shares?

Deep Track Capital, LP and David Kroin may be deemed beneficial owners through their roles but disclaim beneficial ownership of the shares except to the extent of their respective pecuniary interests, according to the disclosure.

Is this Attovia Therapeutics (ATTO) Form 3 reporting a new purchase or sale of shares?

No specific buy or sell transaction is reported. The filing provides an initial statement of beneficial ownership showing Deep Track’s existing holdings of convertible preferred stock and the related common share equivalent.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/10/2026 - 09:26 AM Accepted by SEC EDGAR 08/04/2026 - 09:00 PM Learn about SEC filing dates

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Deep Track Biotechnology Master Fund, Ltd.

(Last) (First) (Middle)

C/O WALKERS CORPORATE LIMITED

190 ELGIN AVE

(Street)

GEORGE TOWN CAYMAN ISLANDS KY1-9001

(City) (State) (Zip)

CAYMAN ISLANDS

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
08/04/2026

3. Issuer Name and Ticker or Trading Symbol
Attovia Therapeutics, Inc. [ ATTO ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

	Form filed by One Reporting Person
X	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Series C Redeemable Convertible Preferred Stock	(1)	(1)	Common Stock	1,957,138	(1)	D(2)

1. Name and Address of Reporting Person^*

Deep Track Biotechnology Master Fund, Ltd.

(Last) (First) (Middle)

C/O WALKERS CORPORATE LIMITED

190 ELGIN AVE

(Street)

GEORGE TOWN CAYMAN ISLANDS KY1-9001

(City) (State) (Zip)

CAYMAN ISLANDS

(Country)

Relationship of Reporting Person(s) to Issuer

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

1. Name and Address of Reporting Person^*

Deep Track Capital, LP

(Last) (First) (Middle)

200 GREENWICH AVENUE, 3RD FLOOR

(Street)

GREENWICH CONNECTICUT 06830

(City) (State) (Zip)

UNITED STATES

(Country)

Relationship of Reporting Person(s) to Issuer

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

1. Name and Address of Reporting Person^*

KROIN DAVID

(Last) (First) (Middle)

C/O DEEP TRACK CAPITAL, LP, 200

GREENWICH AVENUE, 3RD FLOOR

(Street)

GREENWICH CONNECTICUT 06830

(City) (State) (Zip)

UNITED STATES

(Country)

Relationship of Reporting Person(s) to Issuer

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

Explanation of Responses:

1. Each share of Series C Redeemable Convertible Preferred Stock ("Series C Preferred Stock") is convertible at any time at the option of the holder and will automatically convert into shares of the Issuer's common stock ("Common Stock") upon the closing of the Issuer's initial public offering at the applicable conversion ratio of 9.29-for-one. The Series C Preferred Stock has no expiration date.

2. Represents securities held by Deep Track Biotechnology Master Fund, Ltd. Deep Track Capital, LP is the investment manager of Deep Track Biotechnology Master Fund, Ltd. Mr. David Kroin is the managing member of Deep Track Capital GP, LLC, the general partner of Deep Track Capital, LP, and by virtue of such status may be deemed to be the beneficial owner of the shares owned by Deep Track Biotechnology Master Fund, Ltd. Deep Track Capital, LP and Mr. Kroin disclaim beneficial ownership of such shares except to the extent of their respective pecuniary interests..

	Deep Track Biotechnology Master Fund, Ltd. /s/ David Kroin, Director	08/04/2026
	Deep Track Capital, LP /s/ David Kroin, Managing Member of the General Partner of the Investment Adviser	08/04/2026
	/s/ David Kroin	08/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)